Health Outcomes During and After Hormone Therapy: A Comprehensive Look at Women's Health Initiative Data

Long-term analyses clarify the differing effects of menopausal HT formulation and user age at initiation.

Earlier findings from the Women's Health Initiative hormone therapy trials, which enrolled women aged 50 to 79, are well known. Now, investigators have published an outcomes analysis of both trials based on extended cumulative follow-up (median, 13 years) with stratification by age.

Among women randomized to oral conjugated equine estrogens (CEE) + medroxyprogesterone acetate (MPA) compared with placebo, small but statistically significant elevations in risk for invasive breast cancer (hazard ratio, 1.24), stroke (HR, 1.37), and pulmonary embolism (HR, 1.98), as well as reductions in risk for colorectal cancer (HR, 0.62), hip fracture (HR, 0.67), and diabetes (HR, 0.81) occurred during the intervention phase. The changes in risk for all of t…

Reviewing Author

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Andrew M. Kaunitz, MD

Disclosures

RoyaltiesUpToDate

Grant/Research SupportMerck, Mithra, Medicines360

Editorial BoardsContraception; Menopause; Contraceptive Technology Update; OBG Management; Medscape OB/GYN & Women’s Health

Health Outcomes During and After Hormone Therapy: A Comprehensive Look at Women's Health Initiative Data

Topics

Reviewing Author